Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples